CDK Study has enrolled its first patient at Ironwood Cancer and Research Centers – ASCO
ASCO posted on LinkedIn:
“Exciting news! Our CDK Study has enrolled its first patient at Ironwood Cancer and Research Centers, and patient enrollment also has opened at Miami Cancer Institute at Baptist Health South Florida and three St. Joseph’s/Candler locations, including Savannah, Georgia, Bluffton, South Carolina, and Hilton Head Island, South Carolina.
This study is comparing two personalized dosing strategies for CDK4/6 inhibitors in older adults with metastatic Breast Cancer. The trial compares the efficacy and tolerability of a titrated dosing approach to the standard FDA-approved dosing. By starting with a lower dose and gradually increasing it as tolerated, the CDK Study aims to minimize side effects and improve treatment outcomes.
The findings of the CDK Study have the potential to inform clinical practice guidelines and could lead to new standards of care for older adults with metastatic breast cancer.
This important work is a collaboration between dedicated experts and advocates, including: Julie Gralow, Elizabeth Garrett-Mayer, Pam Mangat-Dhaliwal, and Janice Cowden and funded by Patient-Centered Outcomes Research Institute (PCORI).
Learn more about the CDK Study.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023